All In Biotech

Investigational drug · Phase 3

VEGF bispecific antibody

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Squamous Non-small-cell Lung Cancer, Non-squamous Non-small Cell Lung Cancer.

Phase 3

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

2

2 still active

All registered trials

89

Any phase or sponsor naming "VEGF bispecific antibody"

First trial start

2026

Oct 10, 2026

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "VEGF bispecific antibody", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Squamous Non-small-cell Lung Cancer
  • Non-squamous Non-small Cell Lung Cancer

Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Oncology

Largest trials

Live from ClinicalTrials.gov: studies naming "VEGF bispecific antibody" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 3 on PubMed

Also in development for Squamous Non-small-cell Lung Cancer

  • ATX-295Phase 21 trial

    Accent Therapeutics · Advanced Solid Tumors, Breast Cancer Recurrent, Ovarian Cancer

  • VLS-1488Phase 21 trial

    Volastra Therapeutics, Inc. · Advanced Solid Tumor, High Grade Serous Adenocarcinoma of Ovary, Squamous Non-small-cell Lung Cancer

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.